OncoMatch/Clinical Trials/NCT06390774

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Is NCT06390774 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SSGJ-705 for locally advanced, recurrent or metastatic malignancies.

Phase 1RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06390774Data as of May 2026

Treatment: SSGJ-705 — This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Must have adequate organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify